Working… Menu

Clarithromycin in Multiple Myeloma Induction Therapy (CLAIM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02573935
Recruitment Status : Terminated (Suspected side effects to the combination of clarithromycin and VCD (bortezomib, cyclophosphamide and dexamethasone))
First Posted : October 12, 2015
Last Update Posted : September 20, 2016
Danish Myeloma Study Group
Information provided by (Responsible Party):
Henrik Gregersen, Aalborg University Hospital

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
Recruitment Status : Terminated
Actual Primary Completion Date : September 2016
Actual Study Completion Date : September 2016
Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 August 16, 2018
January 29, 2019
2 July 5, 2019
August 15, 2019